Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Buy" from Brokerages

Key Points

• Upstream Bio, Inc. (NASDAQ:UPB) has received a consensus recommendation of "Buy" from four analysts, with an average one-year price target of $56.50.
• Recent earnings reports indicated a loss of ($0.74) EPS, which was below the expected ($0.61), but revenue exceeded expectations at $0.94 million.
• Institutional investors, including Bain Capital and Norges Bank, have increased their stakes in Upstream Bio, reflecting growing confidence in the company's potential.

Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) has earned a consensus rating of "Buy" from the four analysts that are covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $56.50.

UPB has been the subject of a number of recent research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Upstream Bio in a research report on Saturday, September 27th. Wall Street Zen raised shares of Upstream Bio from a "sell" rating to a "hold" rating in a research note on Friday, June 6th.

Hedge Funds Weigh In On Upstream Bio

A number of institutional investors and hedge funds have recently made changes to their positions in UPB. Bain Capital Life Sciences Investors LLC boosted its holdings in Upstream Bio by 6.3% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company's stock valued at $26,786,000 after purchasing an additional 144,216 shares in the last quarter. Norges Bank acquired a new stake in Upstream Bio in the second quarter valued at $10,650,000. Geode Capital Management LLC boosted its stake in shares of Upstream Bio by 57.5% during the second quarter. Geode Capital Management LLC now owns 646,635 shares of the company's stock valued at $7,101,000 after acquiring an additional 235,958 shares during the last quarter. Woodline Partners LP boosted its stake in shares of Upstream Bio by 5.8% during the first quarter. Woodline Partners LP now owns 557,063 shares of the company's stock valued at $3,409,000 after acquiring an additional 30,552 shares during the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new position in Upstream Bio during the first quarter worth about $1,429,000.

Upstream Bio Trading Up 0.2%

Shares of NASDAQ UPB traded up $0.04 during mid-day trading on Friday, reaching $18.63. The company had a trading volume of 239,517 shares, compared to its average volume of 382,172. The business's 50-day moving average is $17.14 and its 200-day moving average is $12.06. Upstream Bio has a 52 week low of $5.14 and a 52 week high of $29.46.

Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.13). The firm had revenue of $0.94 million for the quarter, compared to analysts' expectations of $0.32 million. Upstream Bio had a negative net margin of 3,836.58% and a negative return on equity of 35.90%. Equities research analysts forecast that Upstream Bio will post -4.3 earnings per share for the current year.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.